JP2023524504A5 - - Google Patents
Info
- Publication number
- JP2023524504A5 JP2023524504A5 JP2022566358A JP2022566358A JP2023524504A5 JP 2023524504 A5 JP2023524504 A5 JP 2023524504A5 JP 2022566358 A JP2022566358 A JP 2022566358A JP 2022566358 A JP2022566358 A JP 2022566358A JP 2023524504 A5 JP2023524504 A5 JP 2023524504A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- aldose reductase
- formula
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025180336A JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019186P | 2020-05-01 | 2020-05-01 | |
| US63/019,186 | 2020-05-01 | ||
| US202063019738P | 2020-05-04 | 2020-05-04 | |
| US63/019,738 | 2020-05-04 | ||
| PCT/US2021/029286 WO2021222165A1 (en) | 2020-05-01 | 2021-04-27 | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025180336A Division JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524504A JP2023524504A (ja) | 2023-06-12 |
| JP2023524504A5 true JP2023524504A5 (enExample) | 2024-05-10 |
| JP7788399B2 JP7788399B2 (ja) | 2025-12-18 |
Family
ID=75954272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566358A Active JP7788399B2 (ja) | 2020-05-01 | 2021-04-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
| JP2025180336A Pending JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025180336A Pending JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230121312A1 (enExample) |
| EP (1) | EP4135674A1 (enExample) |
| JP (2) | JP7788399B2 (enExample) |
| KR (1) | KR20230005944A (enExample) |
| CN (1) | CN115996725A (enExample) |
| AU (1) | AU2021264454A1 (enExample) |
| BR (1) | BR112022021845A2 (enExample) |
| CA (1) | CA3176768A1 (enExample) |
| IL (1) | IL297779A (enExample) |
| MX (1) | MX2022013658A (enExample) |
| WO (1) | WO2021222165A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CA3132136A1 (en) | 2019-04-01 | 2020-10-08 | Andrew Wasmuth | Inhibitors of aldose reductase |
| JP2022531466A (ja) | 2019-05-07 | 2022-07-06 | ユニバーシティ オブ マイアミ | 遺伝性ニューロパチーおよび関連障害の処置および検出 |
| GB202400033D0 (en) | 2024-01-02 | 2024-02-14 | Nicolnson Tamara | Therapy i |
| WO2025219948A1 (en) * | 2024-04-17 | 2025-10-23 | Assia Chemical Industries Ltd. | Crystalline forms of govorestat |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
| US5464961A (en) | 1993-09-10 | 1995-11-07 | Olin Corporation | Arcjet anode |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| JPH11512095A (ja) | 1995-08-28 | 1999-10-19 | アメリカン・ホーム・プロダクツ・コーポレイション | アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸 |
| PL179170B1 (pl) | 1995-09-15 | 2000-07-31 | Inst Lekow | Nowe zwiazki,pochodne genisteiny PL PL PL PL |
| SI0776895T1 (en) | 1995-11-20 | 1999-04-30 | Eli Lilly And Company | Protein kinase C inhibitor |
| WO1998042324A2 (en) * | 1997-03-21 | 1998-10-01 | The Regents Of The University Of California | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
| GB9714274D0 (en) * | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| HRP20221430T1 (hr) | 2010-07-16 | 2023-01-06 | The Trustees Of Columbia University In The City Of New York | Inhibitori aldozoreduktaze i njihova uporaba |
| WO2017038505A1 (ja) | 2015-09-01 | 2017-03-09 | 株式会社村田製作所 | コイル内蔵部品 |
| RS61239B1 (sr) * | 2016-06-21 | 2021-01-29 | Univ Columbia | Inhibitori aldozne reduktaze i postupci korišćenja |
| IL272246B2 (en) * | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
-
2021
- 2021-04-27 WO PCT/US2021/029286 patent/WO2021222165A1/en not_active Ceased
- 2021-04-27 AU AU2021264454A patent/AU2021264454A1/en active Pending
- 2021-04-27 MX MX2022013658A patent/MX2022013658A/es unknown
- 2021-04-27 CA CA3176768A patent/CA3176768A1/en active Pending
- 2021-04-27 BR BR112022021845A patent/BR112022021845A2/pt unknown
- 2021-04-27 CN CN202180044285.7A patent/CN115996725A/zh active Pending
- 2021-04-27 IL IL297779A patent/IL297779A/en unknown
- 2021-04-27 KR KR1020227042040A patent/KR20230005944A/ko active Pending
- 2021-04-27 JP JP2022566358A patent/JP7788399B2/ja active Active
- 2021-04-27 EP EP21726266.6A patent/EP4135674A1/en active Pending
-
2022
- 2022-10-28 US US18/050,627 patent/US20230121312A1/en not_active Abandoned
-
2024
- 2024-02-01 US US18/429,719 patent/US20240238288A1/en active Pending
-
2025
- 2025-10-27 JP JP2025180336A patent/JP2026012262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524504A5 (enExample) | ||
| JP5389030B2 (ja) | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン | |
| Lin et al. | The protective effect of hesperetin in osteoarthritis: an in vitro and in vivo study | |
| US20210228564A1 (en) | Pyrvinium pamoate therapies and methods of use | |
| JP2021529780A5 (enExample) | ||
| JP2021511360A5 (enExample) | ||
| JP2020528938A5 (enExample) | ||
| US20110003013A1 (en) | Method of increasing metabolism | |
| US9814741B2 (en) | Methods relating to DNA-sensing pathway related conditions | |
| WO2016200726A1 (en) | Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors | |
| US12221433B2 (en) | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| JP2022547452A (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| Humphries et al. | Activation of human meningeal cells is modulated by lipopolysaccharide (LPS) and non‐LPS components of Neisseria meningitidis and is independent of Toll‐like receptor (TLR) 4 and TLR2 signalling | |
| KR20180073606A (ko) | 아포리포프로테인 (a) 발현 조정 | |
| Judd et al. | BCL-XL–targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors | |
| CN115998872B (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| TW202340463A (zh) | 調節補體因子b之組合物及其使用方法 | |
| AU2010236181B2 (en) | Method of treating hepatocellular carcinoma | |
| JP7080346B2 (ja) | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート | |
| JP2021522327A5 (enExample) | ||
| JP2025098099A (ja) | ブルトン型チロシンキナーゼ阻害剤の投薬 | |
| CN104159589A (zh) | 肝脏状况的治疗 | |
| WO2018011376A1 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| WO2020128816A2 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| Wang et al. | Nifuroxazide inhibits the growth of glioblastoma and promotes the infiltration of CD8 T cells to enhance antitumour immunity |